Diagnostic Equivalence of the Skin Prick Test Tape vs. Conventional Skin PrickTest

NCT ID: NCT03820154

Last Updated: 2019-01-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 75 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-03-01
• Study Completion Date: 2019-07-30

Brief Summary

Testing of a new ready-to-use Tape in comparison to the currently used skin prick test for the diagnosis of allergies. Assessment of clinical equivalence of the SPT Tape for representative common inhalant allergens to conventional SPT in terms of wheal reaction positivity and overall safety. Tests are performed in patients who have a medical history of relevant allergic rhinitis to any of the tested allergens.

Detailed Description

An open-label, single site bridging study. Subjects with a history of in-halation allergies will be tested in parallel with the SPT Tape and with the conventional SPT procedure using one forearm each.

In each patient, a panel of 8 allergens with the SPT Tape and with the conventional SPT is applied on the two forearms one time only.

The following Soluprick® allergens and control solutions will be evaluated:

Positive control, negative control, Phleum pratense, birch, Dermatophagoides pteronyssinus, D. farinae, dog dander, cat dander, mugwort, Alternaria sp. The allergens used for the SPT and the SPT Tape are identical Soluprick allergen solutions; allergens will be applied in the same location and order on both arms.

Conditions

Allergic Rhinitis; Allergic Asthma; Allergic Conjunctivitis; Food Allergy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Skin Prick Test TAPE

The Skin Prick Test Tape is an innovative sterile "all-in" drug carrying 8 allergens and 2 control solutions including prick needles in one Tape for easy use and standardization. Single use. Reading of wheal reactions after 15 minutes, facilitated by stripes with the allergen names.

Group Type: ACTIVE_COMPARATOR

Skin Prick Test TAPE

Intervention Type: DIAGNOSTIC_TEST

Skin Prick Testing with a Tape, integrating the allergens and needles

Skin Prick Test

The conventional SPT is the world-wide standard in allergy Type 1 diagnosis for inhalant and food allergens. Drops of allergens are applied to the forearm and, with the help of a lancet, brought into the skin. Reading of wheal reactions after 15 minutes.

Group Type: ACTIVE_COMPARATOR

Skin Prick Test

Intervention Type: DIAGNOSTIC_TEST

Skin Prick Testing with inhalant allergens

Interventions

Skin Prick Test

Skin Prick Testing with inhalant allergens

Intervention Type: DIAGNOSTIC_TEST

Skin Prick Test TAPE

Skin Prick Testing with a Tape, integrating the allergens and needles

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Subjects will be included only, if

1. they were informed about the nature, meaning, and scope of the study, and if they provided written consent to their participation

2. they are at least 18 years of age,

3. they have a history of allergic rhinitis due to grass and/or birch pollen, house dust mites, mugwort, cat and/or dog dander, and/or Alternaria since 2 years or more

Exclusion Criteria

• Subjects may not be included, if

1. they are impaired in understanding nature, meaning, and the scope of the study, or are incapable of giving written informed consent,

2. they suffer from diseases, show other conditions, or take medications, which might impact the skin tests or might contradict the correct conduct and evaluation of the study. In particular this includes the following:

1. acute allergy,

2. history of systemic reactions or hypersensitivity to allergens, abuse of drugs or alcohol

3. severe diseases,

4. impaired reactivity of the skin (e.g. hyperkeratosis, ichthyosis, urticaria factitia) and acute chronic eczema in the skin test areas, skin infections,

5. pregnancy or nursing,

6. treatment with β-blockers,

7. treatment with antihistamines or systemic glucocorticoids during the last 4 weeks, with astemizol during the last 12 weeks,

8. treatment with tricyclic antidepressants benzodiazepines, and neuroleptic drugs which may have histamine-antagonistic effects during the last 2 weeks,

9. participation in any other medication study at the study time

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Prof. Dr. Claus Bachert BVBA

INDIV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Martin Wagenmann, MD

Role: PRINCIPAL_INVESTIGATOR

University pf Düsseldorf, Germany

Central Contacts

Claus U Bachert, MD

Role: CONTACT

claus.bachert@ugent.be

+32473310902

Other Identifiers

CBauchert

Identifier Type: -

Identifier Source: org_study_id